THERAVECTYS,
a fully-integrated discovery and clinical development biotechnology
company focusing on the development of therapeutic vaccines and
immunotherapies, announces the grant of its European Patent “Lentiviral
Vectors Containing an MHC Class I Promoter” only two years after its
initial filing (website).
The patent describes and claims lentiviral vectors using MHC class I
gene promoters, “methods of making the vectors and methods of using
them, including medicinal uses”.
Within the lentiviral vectors, the role of the promoter is to control
the in vivo expression of the vectorized antigens. MHC class I
promoters are naturally highly active in Antigen Presenting Cells thus
inducing a broad, intense and long-lasting CD4+/CD8+ immune response following
the injection of THERAVECTYS vaccines. The resulting stimulation of
the cellular immune response leads to the elimination of the targeted
infected or carcinogenic cells as well as all cells transduced by the
vector post-injection. The use of this family of promoters
contributes to further enhance the efficacy and safety of THERAVECTYS
lentiviral vector platform.
THERAVECTYS owns over 20
patent families, either developed in-house or
exclusively licensed from the Pasteur Institute from which the
company has secured exclusive worldwide rights for the use of
lentiviral vectors in vaccination and immunotherapy applications.
THERAVECTYS has implemented a systematic approach to strengthen its
intellectual property by protecting:
-
Any new indication-specific vaccines and immunotherapeutic
candidates (including those derived from the company’s proprietary
Chimeric Antigen Receptors technology);
-
All improvements brought to the lentiviral vector platform and
the bioproduction process.
“I am extremely pleased with the grant of this important
European patent protecting our MHC Class I promoters. It confirms that
THERAVECTYS is at the forefront of lentiviral vectors optimization
including packaging, delivery, expression, and immune response.”
says Dr. Cécile BAUCHE, CSO. “This achievement clearly
demonstrates our ability to build one of the broadest and most valuable
lentiviral vectors patent portfolios in the world”.
“The protection and the defense of our innovation is at the heart of
our overall strategy” says Renaud Vaillant, CEO. “This
important milestone not only demonstrates our ability to stay ahead of
the game but more importantly creates a key competitive advantage which
we intend to transform into long-term value for ourselves, our partners
and our investors”.
About THERAVECTYS
THERAVECTYS is a privately-owned, fully-integrated discovery and
clinical development biotech company originating from the Pasteur
Institute.
THERAVECTYS capitalizes over 15 years of fundamental research in the
field of lentiviral vectors and has secured worldwide exclusive
rights to Pasteur Institute intellectual property.
Based on its lentiviral vector technology platform, THERAVECTYS develops
therapeutic vaccines and immunotherapies to fight cancers and infectious
diseases, including a proprietary and differentiated CAR T-cell
technology platform.
The company is strongly supported by renowned investors and
former global biopharmaceutical executives and is rapidly
progressing in its R&D activities and in-house GMP production
capabilities.
Alone and in collaboration with partners, THERAVECTYS is accelerating
its clinical development programs and is planning to initiate two
additional phase I/II clinical trials in oncology in 2015.
Follow us:
Twitter
- Google
- LinkedIn
Copyright Business Wire 2014